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A prominent R wave in V1 but not in V2 is a specific sign of a large
lateral infarction: Algerian study
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Introduction and Objectives: In the absence of right ventricular hyper-
trophy or bundle-branch block, a prominent R wave in V1 or V2 is considered
to reflect a lateral myocardial infarction. We investigated the differences in
infarct location and size between patients with prominent R wave in V1 and
those with prominent R wave in V2.
Methods: We studied 50 patients with a previous first infarction involving
left ventricular inferior and/or lateral wall at myocardial scintigraphy
Results: A prominent R wave in V1 was present in 8 patients (16%), in
V2 in 23 (46%). At myocardial scintigraphy, the infarction involved the infe-
rior wall in 11 patients (22%), the lateral wall in 6 (12%), and both walls in
33 patients (66%). The sensitivity of a prominent R wave in V1 in detecting
a lateral infarction was low (17.9%), while the specificity was high (90.9%).
The sensitivity and specificity of a prominent R wave in V2 were 46.2% and
54.5%, respectively. In patients with a prominent R wave in V1, infarct size
and lateral extent were greater than in patients without this pattern (P<.005
and <.0.01 respectively). In patients with a prominent R wave in V2, infarct
size, lateral extent were not different from patients without this pattern.
Conclusions: Only a prominent R wave in V1 is a specific sign of large
lateral infarction.
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Bioresorbable everolimus eluting stents in acute coronary syndroms.
Preliminary implantation data and follow up of 40 patients
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laine Dufaitre, Laurent Meille, Catherine Meuleman, Frederic Ortuno
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Between February 20133 and October 2014, 105 patients aged 64.2 (25-94)
underwent coronary artery stenting with at least one Absorb Biovascular Scaf-
fold (BVS).
Of these procédures 40 were realized in the setting of acute coronary
syndroms (15 ST elevation myocardial Infarction – STEMI – and 25 non
STEMI). 42 BVS have been implanted through a radial approach on the
culprit lesion under angiographic control alone. Left anterior descending
artery was involved in 19, the right coronary artery in 14 and the left circum-
flex in 7 patients.18 patients had multivesseldesease and underwent a second
staged procedure before discharge with BVS or metallic drug eluting stents
implantation
In hospital stay was event free for all 40 patients. All were discharged
under conventionnal dual antiplatellet therapy.
Out hospital follow up (11.2 months –2-22): no clinical event occured. One
patient experienced 70% restenosis proximal to the stent and underwent new
stenting with metallic drug eluting stent (TLR: 2.5%). 
Conclusions: at that time our preliminary data confirm the safety at mid
term of the BVS device in acute coronary syndroms.
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Context: Angioplasty with stent placement, used to treat symptomatic
atherosclerosis plaques, is frequently complicated by restenosis. This
pathology is characteried by fibroproliferative and immuno-inflammatory
mechanisms of the arterial wall, called intimal hyperplasia (IH).
Aims: Our previous results demonstrated that phosphoinositide 3-kinase γ
(PI3Kγ ) was a key mediator of inflammatory processes of the arterial wall
leading to atherosclerosis. We now proposed this enzyme as a potential
clinical target to prevent vascular damages occuring after arterial lesion
leading to IH. As cellular and molecular aspects of IH are still incompletely
described, we intended to offer a better understanding ofimmune responses
involved in this pathology.
Results: Using a mouse model of arterial mechanical injury, we showed
that PI3Kγ -deficient mice and mice expressing a catalytically-inactive PI3Kγ
(PI3Kγ  KD) showed reduced arterial occlusion and accumulation of mono-
cytes and T cells around site of vascular lesion. The transfer of PI3Kγ  KD
CD4+ T cells into Rag2-deficient mice greatly reduced vascular occlusion
compared to WT cells, clearly demonstrating the involvement of PI3Kγ  in
CD4+ T cells during IH formation. In addition, we found that IH is associated
with increased levels of Th1 and Th17 cytokines. A specific decrease in the
Th1 response was observed in the absence of PI3Kγ  activity, leading to
decreased chemokine production by smooth muscle cells. Finally, we show
that a short period of treatment with a PI3Kγ  inhibitor decreased IH develop-
ment in arterial mechanical injury in mice but also in a rat carotid artery bal-
loon injury model demonstrating the therapeutic potential of this inhibitor.
Conclusion: Our work pintpoint PI3Kγ  as a good target for IH prevention
and brings new insights in the immune biology of the disease.
April 02nd, Thursday 2015

